Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
Friday, 19 April 2024 () SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated April 18, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. Specifically, the letter states that the Company is not in compliance with the con
Friday, 19 April 2024 ()
